Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection

Carcinogenesis

Volumn 28, Issue 6, 2007, Pages 1241-1246

  Molleví, David G ^a   Serrano, Teresa ^b   Ginestà, Mireia ^a   Valls, Joan ^a,c   Torras, Jaume ^b   Navarro, Matilde ^a   Ramos, Emilio ^b   Germà, Josep R ^a   Jaurrieta, Eduardo ^b   Moreno, Víctor ^a,c   Figueras, Joan ^d   Capellà, Gabriel ^a   Villanueva, Alberto ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; PROTEIN P21; PROTEIN P53;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SINGLE STRAND CONFORMATION POLYMORPHISM; UNIVARIATE ANALYSIS;

ADULT; AGED; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447295930     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm012     Document Type: Article

References (40)

1. Parkin,D.M. et al. (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer, 54, 594-606.
2. Bengmark,S. et al. (1969) The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinomas by laparotomy. Cancer, 23, 198-202.
3. Scheele,J. et al. (1995) Resection of colorectal liver metastases. World J. Surg., 19, 59-71.
4. Fong,Y. et al. (1997) Liver resection for colorectal metastases. J. Clin. Oncol., 15, 938-946.
5. Saltz,L.B. et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N. Engl. J. Med., 343, 905-914.
6. Giacchetti,S. et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as firstline treatment of metastatic colorectal cancer. J. Clin. Oncol. 18, 136-147.
7. Ohlsson,B. et al. (1998) Resection of colorectal liver metastases: 25-year experience. World J. Surg., 22, 268-277.
8. Jaeck,D. et al. (1997) Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br. J. Surg., 84, 977-980.
9. Figueras,J. et al. (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br. J. Surg., 88, 980-985.
10. Makuuchi,M. et al. (1990) Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report. Surgery, 107, 521-527.
11. Valls,C. et al. (2001) Hepatic metastases from colorectal cancer: preoperative detection and assessment of respectability with helical CT. Radiology, 218, 55-60.
12. Makuuchi,M. et al. (1998) History of intraoperative ultrasound. Ultrasound Med. Biol., 24, 1229-1242.
13. Chung,D.C. (2000) The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis. Gastroenterology, 119, 854-865.
14. Wang,T.L. et al. (2004) Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl Acad. Sci. USA, 101, 3089-3094.
15. Rudmik,L.R. et al. (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J. Surg. Oncol., 92, 347-359.
16. Malkhosyan,S. et al. (1998) Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting. Proc. Natl Acad. Sci USA, 95, 10170-10175.
17. Diep,C.B. et al. (2003) Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis. Genes Chromosomes Cancer, 36, 189-197.
18. Saha,S. et al. (2001) A phosphatase associated with metastasis of colorectal cancer. Science, 294, 1343-1346.
19. Vogelstein,B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
20. Iacopetta,B. et al. (2006) Functional categories of TP53 mutation in colorectal cancer: Results of an International Collaborative study. Ann. Oncol., 17, 842-847.
21. Tullo,A. et al. (1999) Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin. Cancer Res., 5, 3523-3528.
22. Saw,R.P. et al. (2002) p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br. J. Surg., 89, 1409-1415.
23. de Jong,K.P. et al. (2005) P53 mutation analysis of colorectal liver metastases: Relation to actual survival, angiogenic status, and p53 overexpression. Clin. Cancer Res., 11, 4067-4073.
24. Miyaki,M. et al. (2002) High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas. Oncogene, 21, 6689-6693.
25. Hamelin,R. et al. (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106, 42-48.
26. Goh,H.S. et al. (1995) P53 point mutation and survival in colorectal cancer patients. Cancer Res., 55, 5217-5221.
27. Russo,A. et al. (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol., 23, 7518-7528.
28. Samowitz,W.S. et al. (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer, 99, 597-602.
29. Sturm,I. et al. (1999) Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J. Clin. Oncol., 17, 1364-1374.
30. Yang,Y. et al. (2001) P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer, 91 727-736.
31. Donato,N. et al. (1994) Retrospective study on adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. Eur. J. Surg. Oncol., 20, 454-460.
32. Minagawa,M. et al. (2000) Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer Long-term results. Ann. Surg., 231, 487-499.
33. Etienne,M.C. et al. (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses. J. Clin. Oncol., 20, 2832-2843.
34. Russo,A. et al. (1998) Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif., 31, 139-153.
35. Albanese,I. et al. (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem. Biophys. Res. Commun., 325 784-791.
36. Tortola,S. et al. (1999) p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J. Clin. Oncol., 17, 1375-1381.
37. Iacopetta,B. (2003) T?53 mutation in colorectal cancer. Hum. Mutat. 21, 271-276.
38. Nitti,D. et al. (1998) Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: An independent prognostic factor of survival. Eur. J. Cancer, 34, 851-855.
39. Crowe,P.J. et al. (2001) Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J. Surg., 25, 996-1001.
40. Castells,A. et al. (1999) K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance. J. Clin. Oncol., 17, 578-584.